Science News

COVID-19 Professional Resources
The AHA is working to ensure optimal care for patients with cardiovascular disease who contract coronavirus (COVID-19). Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with COVID-19. Here are some helpful resources for health systems, clinics, care providers, patients and the public.
AHA Journals This Week | July 6, 2020
07/06/2020 | AHA Journals This Week July 6, 2020
Cardiac Amyloidosis: Evolving Diagnosis and Management
06/01/2020 | This scientific statement is intended to inform clinical practice and facilitate management of transthyretin cardiac amyloidosis (ATTR-CM). The statement covers current diagnostic and treatment strategies while also identifying the lingering areas of uncertainty.
Collaboration with LLNL shares COVID-19 research data
05/22/2020 | The American Heart Association is pleased to announced that our collaboration with Lawrence Livermore National Labs (LLNL) on the protein atlas developed through the AHA Center for Accelerated Discovery is being leveraged to help accelerate discovery of therapeutic antibodies or antiviral drugs for SARS-CoV-2, the virus that causes COVID-19.
Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients
05/07/2020 | Acute venous thromboembolism (VTE), comprising deep venous thrombosis (DVT) of the legs or pelvis and pulmonary embolism (PE), is a frequent, costly complication in hospitalized patients.
Social Determinants of Health in the Care of Patients With Heart Failure
04/30/2020 | Heart failure (HF) is a clinical syndrome that affects over 6.5 million Americans, with an estimated 550,000 new cases diagnosed each year.
Family Caregiving for Individuals With Heart Failure
04/30/2020 | Heart failure (HF) affects over 6 million adults in the United States and 26 million globally, with prevalence increasing due to the combined effects of social and lifestyle determinants and an aging population.
AHA, ACC redefine guideline processes
04/27/2020 | In a historic move, the AHA and ACC re-visited their 30-year partnership of jointly producing clinical practice guidelines for the cardiovascular community.
HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19
03/16/2020 | Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with coronavirus disease 2019 (COVID-19).